{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:57:13Z","timestamp":1791619033528,"version":"4.3.4"},"reference-count":280,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK116720-01"],"award-info":[{"award-number":["K23 DK116720-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005627","name":"Thrasher Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008813","name":"International Society for Pediatric and Adolescent Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011866","name":"Colorado Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012876","name":"Center for Women's Health Research, University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diabetic kidney disease remains the most common cause of end-stage kidney disease in the world. Despite reductions in incidence rates of myocardial infarction and stroke in people with diabetes over the past 3 decades, the risk of diabetic kidney disease has remained unchanged, and may even be increasing in younger individuals afflicted with this disease. Accordingly, changes in public health policy have to be implemented to address the root causes of diabetic kidney disease, including the rise of obesity and diabetes, in addition to the use of safe and effective pharmacological agents to prevent cardiorenal complications in people with diabetes. The aim of this article is to review the mechanisms of pathogenesis and therapies that are either in clinical practice or that are emerging in clinical development programs for potential use to treat diabetic kidney disease.<\/jats:p>","DOI":"10.1210\/endrev\/bnz010","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T09:37:33Z","timestamp":1571650653000},"page":"202-231","source":"Crossref","is-referenced-by-count":145,"title":["The New Biology of Diabetic Kidney Disease\u2014Mechanisms and Therapeutic Implications"],"prefix":"10.1210","volume":"41","author":[{"given":"Yuliya","family":"Lytvyn","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"van Raalte","sequence":"additional","affiliation":[{"name":"Diabetes Center, Department of Internal Medicine, VU University Medical Center, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Sydney, Australia"},{"name":"Department of Clinical Pharmacology, University of Groningen, Groningen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"issue":"1 Suppl 1","key":"2021121110281285400_CIT0001","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2010.10.007","article-title":"US renal data system 2010 annual data report","volume":"57","author":"Collins","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2021121110281285400_CIT0002","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","article-title":"Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"J Clin Med."},{"issue":"4","key":"2021121110281285400_CIT0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"17","key":"2021121110281285400_CIT0004","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1073\/pnas.82.17.5963","article-title":"Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy","volume":"82","author":"Zatz","year":"1985","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021121110281285400_CIT0005","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.ASN.0000093460.24823.5B","article-title":"Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator","volume":"15 Suppl 1","author":"Ziyadeh","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"2021121110281285400_CIT0006","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14728222.2019.1624721","article-title":"Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies","volume":"23","author":"Warren","year":"2019","journal-title":"Expert Opin Ther Targets."},{"issue":"6","key":"2021121110281285400_CIT0007","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1681\/ASN.2005080872","article-title":"Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes","volume":"17","author":"Sochett","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"2021121110281285400_CIT0008","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1055\/s-2007-979092","article-title":"Lack of effect of captopril on glomerular hyperfiltration in normoalbuminuric normotensive insulin-dependent diabetic patients","volume":"29","author":"de Azevedo","year":"1997","journal-title":"Horm Metab Res."},{"issue":"3","key":"2021121110281285400_CIT0009","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2215\/CJN.03691106","article-title":"Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors","volume":"2","author":"Ficociello","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"issue":"20","key":"2021121110281285400_CIT0010","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"2021121110281285400_CIT0011","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11906-008-0064-4","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"10","author":"Vidt","year":"2008","journal-title":"Curr Hypertens Rep."},{"issue":"23","key":"2021121110281285400_CIT0012","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"2021121110281285400_CIT0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11892-019-1123-8","article-title":"Mineralocorticoid antagonism and diabetic kidney disease","volume":"19","author":"Lytvyn","year":"2019","journal-title":"Curr Diab Rep."},{"issue":"10184","key":"2021121110281285400_CIT0014","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"2021121110281285400_CIT0015","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res."},{"issue":"1","key":"2021121110281285400_CIT0016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5527\/wjn.v4.i1.74","article-title":"ACE and ACE2 in kidney disease","volume":"4","author":"Mizuiri","year":"2015","journal-title":"World J Nephrol."},{"issue":"2","key":"2021121110281285400_CIT0017","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/HYPERTENSIONAHA.110.164244","article-title":"Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2","volume":"57","author":"Zhong","year":"2011","journal-title":"Hypertension."},{"issue":"6","key":"2021121110281285400_CIT0018","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.2353\/ajpath.2006.051091","article-title":"Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis","volume":"168","author":"Oudit","year":"2006","journal-title":"Am J Pathol."},{"issue":"5","key":"2021121110281285400_CIT0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/sj.ki.5002373","article-title":"ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice","volume":"72","author":"Soler","year":"2007","journal-title":"Kidney Int."},{"issue":"3","key":"2021121110281285400_CIT0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.2012.83","article-title":"Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice","volume":"82","author":"Nadarajah","year":"2012","journal-title":"Kidney Int."},{"issue":"12","key":"2021121110281285400_CIT0021","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/ki.2008.497","article-title":"Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease","volume":"74","author":"Reich","year":"2008","journal-title":"Kidney Int."},{"issue":"4","key":"2021121110281285400_CIT0022","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1053\/j.ajkd.2007.11.022","article-title":"Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls","volume":"51","author":"Mizuiri","year":"2008","journal-title":"Am J Kidney Dis."},{"issue":"1-2","key":"2021121110281285400_CIT0023","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/molmed.2010.00111","article-title":"Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition","volume":"17","author":"Liu","year":"2011","journal-title":"Mol Med."},{"issue":"3","key":"2021121110281285400_CIT0024","doi-asserted-by":"crossref","first-page":"F585","DOI":"10.1152\/ajprenal.00538.2009","article-title":"Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7\/MAS-1-dependent pathways","volume":"299","author":"Burns","year":"2010","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"2021121110281285400_CIT0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v3.i1.1","article-title":"Renal hyperfiltration related to diabetes mellitus and obesity in human disease","volume":"3","author":"Sasson","year":"2012","journal-title":"World J Diabetes."},{"issue":"7","key":"2021121110281285400_CIT0026","doi-asserted-by":"crossref","first-page":"R710","DOI":"10.1152\/ajpregu.00286.2012","article-title":"Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus","volume":"303","author":"Cherney","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"3","key":"2021121110281285400_CIT0027","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2337\/db07-1230","article-title":"The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes","volume":"57","author":"Cherney","year":"2008","journal-title":"Diabetes."},{"issue":"1","key":"2021121110281285400_CIT0028","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.dsx.2018.11.054","article-title":"Diabetic nephropathy: An update on pathogenesis and drug development","volume":"13","author":"Tan","year":"2019","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"2021121110281285400_CIT0029","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.dsx.2018.11.014","article-title":"Albuminuric and non-albuminuric patterns of chronic kidney disease in type 2 diabetes","volume":"13","author":"Klimontov","year":"2019","journal-title":"Diabetes Metab Syndr."},{"issue":"3","key":"2021121110281285400_CIT0030","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1681\/ASN.2015111230","article-title":"Anti-TGF-\u03b21 antibody therapy in patients with diabetic nephropathy","volume":"28","author":"Voelker","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"2021121110281285400_CIT0031","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2215\/CJN.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"2021121110281285400_CIT0032","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"2021121110281285400_CIT0033","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"2021121110281285400_CIT0034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2337\/dc17-1467","article-title":"Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON","volume":"41","author":"Jun","year":"2018","journal-title":"Diabetes Care."},{"issue":"2","key":"2021121110281285400_CIT0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11892-015-0708-0","article-title":"Diabetic kidney disease in adolescents with type 2 diabetes: new insights and potential therapies","volume":"16","author":"Bjornstad","year":"2016","journal-title":"Curr Diab Rep."},{"key":"2021121110281285400_CIT0036","article-title":"Resurgence in diabetes-related complications","author":"Gregg","journal-title":"JAMA"},{"issue":"16","key":"2021121110281285400_CIT0037","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med."},{"issue":"10","key":"2021121110281285400_CIT0038","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"issue":"10","key":"2021121110281285400_CIT0039","doi-asserted-by":"crossref","first-page":"e0186910","DOI":"10.1371\/journal.pone.0186910","article-title":"The effect of sodium\/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome","volume":"12","author":"Cherney","year":"2017","journal-title":"Plos One."},{"issue":"1","key":"2021121110281285400_CIT0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int."},{"issue":"8","key":"2021121110281285400_CIT0041","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.2337\/dc18-0394","article-title":"Acute effect of empagliflozin on fractional excretion of sodium and eGFR in youth with type 2 diabetes","volume":"41","author":"Bjornstad","year":"2018","journal-title":"Diabetes Care."},{"issue":"5","key":"2021121110281285400_CIT0042","doi-asserted-by":"crossref","first-page":"F1406","DOI":"10.1152\/ajprenal.00384.2017","article-title":"Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease","volume":"315","author":"Le\u00f3n Jim\u00e9nez","year":"2018","journal-title":"Am J Physiol Renal Physiol."},{"issue":"3","key":"2021121110281285400_CIT0043","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int."},{"issue":"6","key":"2021121110281285400_CIT0044","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med."},{"issue":"9","key":"2021121110281285400_CIT0045","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"2021121110281285400_CIT0046","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"3","key":"2021121110281285400_CIT0047","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41581-018-0106-3","article-title":"Sodium transport in diabetes: two sides to the coin","volume":"15","author":"Lovshin","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"2","key":"2021121110281285400_CIT0048","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care."},{"issue":"4","key":"2021121110281285400_CIT0049","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"issue":"7","key":"2021121110281285400_CIT0050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"22","key":"2021121110281285400_CIT0051","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"2021121110281285400_CIT0052","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"2021121110281285400_CIT0053","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"2021121110281285400_CIT0054","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","author":"Sugiyama","year":"2018","journal-title":"Intern Med."},{"issue":"1","key":"2021121110281285400_CIT0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","article-title":"Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study","volume":"16","author":"Shigiyama","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"2021121110281285400_CIT0056","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"2021121110281285400_CIT0057","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload","volume":"32","author":"Shi","year":"2019","journal-title":"Am J Hypertens."},{"issue":"4","key":"2021121110281285400_CIT0058","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000074","article-title":"Early diabetic nephropathy in type 1 diabetes: new insights","volume":"21","author":"Bjornstad","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"5","key":"2021121110281285400_CIT0059","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcjd.2014.05.006","article-title":"Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?","volume":"38","author":"Cherney","year":"2014","journal-title":"Can J Diabetes."},{"issue":"3","key":"2021121110281285400_CIT0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcjd.2017.06.008","article-title":"Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new","volume":"42","author":"Goldenberg","year":"2018","journal-title":"Can J Diabetes."},{"issue":"1","key":"2021121110281285400_CIT0061","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"issue":"10","key":"2021121110281285400_CIT0062","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia."},{"issue":"1","key":"2021121110281285400_CIT0063","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"issue":"4","key":"2021121110281285400_CIT0064","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation."},{"issue":"5","key":"2021121110281285400_CIT0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation."},{"issue":"5","key":"2021121110281285400_CIT0066","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int."},{"key":"2021121110281285400_CIT0067","first-page":"ajprenal 00043 02017","article-title":"Urinary adenosine excretion in type 1 diabetes","author":"Rajasekeran","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"2021121110281285400_CIT0068","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrti\u0107","year":"2014","journal-title":"Diabetologia."},{"issue":"24","key":"2021121110281285400_CIT0069","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","article-title":"Single-nephron glomerular filtration rate in healthy adults","volume":"376","author":"Denic","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"2021121110281285400_CIT0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S2213-8587(19)30080-4","article-title":"Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors\u2019 reply","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021121110281285400_CIT0071","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"2021121110281285400_CIT0072","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"2021121110281285400_CIT0073","first-page":"Abstract S-157","volume-title":"Dapagliflozin Reduces Measured GFR by Reducing Renal Efferent Arteriolar Resistance in Type 2 Diabetes","author":"Van Bommel","year":"2019"},{"issue":"5","key":"2021121110281285400_CIT0074","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2021121110281285400_CIT0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"9896","key":"2021121110281285400_CIT0076","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet."},{"issue":"9","key":"2021121110281285400_CIT0077","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia."},{"issue":"8","key":"2021121110281285400_CIT0078","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021121110281285400_CIT0079","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"2021121110281285400_CIT0080","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"2021121110281285400_CIT0081","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.kint.2018.05.026","article-title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials","volume":"94","author":"van Raalte","year":"2018","journal-title":"Kidney Int."},{"issue":"7","key":"2021121110281285400_CIT0082","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia."},{"key":"2021121110281285400_CIT0083","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial","author":"Mosenzon","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2021121110281285400_CIT0084","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"24","key":"2021121110281285400_CIT0085","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"3","key":"2021121110281285400_CIT0086","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"2021121110281285400_CIT0087","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"3","key":"2021121110281285400_CIT0088","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"issue":"12","key":"2021121110281285400_CIT0089","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"2021121110281285400_CIT0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"2021121110281285400_CIT0091","doi-asserted-by":"crossref","first-page":"F1519","DOI":"10.1152\/ajprenal.00211.2018","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side","volume":"315","author":"Dieter","year":"2018","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"2021121110281285400_CIT0092","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"23","key":"2021121110281285400_CIT0093","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"issue":"13","key":"2021121110281285400_CIT0094","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"issue":"19","key":"2021121110281285400_CIT0095","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2021121110281285400_CIT0096","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"2021121110281285400_CIT0097","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med."},{"issue":"22","key":"2021121110281285400_CIT0098","first-page":"2197","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med."},{"issue":"11","key":"2021121110281285400_CIT0099","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021121110281285400_CIT0100","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"2021121110281285400_CIT0101","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021121110281285400_CIT0102","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","author":"Gerstein","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2021121110281285400_CIT0103","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","author":"Gerstein","year":"2019","journal-title":"Lancet (London, England)."},{"issue":"9","key":"2021121110281285400_CIT0104","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"2021121110281285400_CIT0105","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology."},{"issue":"11","key":"2021121110281285400_CIT0106","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc16-1371","article-title":"Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Tonneijck","year":"2016","journal-title":"Diabetes Care."},{"issue":"2","key":"2021121110281285400_CIT0107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"2021121110281285400_CIT0108","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia."},{"issue":"6","key":"2021121110281285400_CIT0109","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","article-title":"Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells","volume":"297","author":"Carraro-Lacroix","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"2021121110281285400_CIT0110","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol."},{"issue":"10","key":"2021121110281285400_CIT0111","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"2021121110281285400_CIT0112","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2021121110281285400_CIT0113","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care."},{"issue":"2","key":"2021121110281285400_CIT0114","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-018-1826-7","article-title":"Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-\u03b1 cell signaling pathway","volume":"64","author":"Zhou","year":"2019","journal-title":"Endocrine."},{"issue":"1","key":"2021121110281285400_CIT0115","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1038\/s41598-017-02838-2","article-title":"GLP-1 receptor signalling promotes \u03b2-cell glucose metabolism via mTOR-dependent HIF-1\u03b1 activation","volume":"7","author":"Carlessi","year":"2017","journal-title":"Sci Rep."},{"issue":"3","key":"2021121110281285400_CIT0116","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bph.14534","article-title":"Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries","volume":"176","author":"Bangshaab","year":"2019","journal-title":"Br J Pharmacol."},{"issue":"11","key":"2021121110281285400_CIT0117","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/db17-1212","article-title":"Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy","volume":"67","author":"Moellmann","year":"2018","journal-title":"Diabetes."},{"issue":"2","key":"2021121110281285400_CIT0118","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40519-016-0352-y","article-title":"GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products","volume":"22","author":"Guglielmi","year":"2017","journal-title":"Eat Weight Disord."},{"key":"2021121110281285400_CIT0119","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency","author":"Levey","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"2021121110281285400_CIT0120","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation."},{"issue":"8","key":"2021121110281285400_CIT0121","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2337\/dc17-0061","article-title":"Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1\u03b11-67 in patients with type 2 diabetes","volume":"40","author":"Lovshin","year":"2017","journal-title":"Diabetes Care."},{"issue":"12","key":"2021121110281285400_CIT0122","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"2021121110281285400_CIT0123","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care."},{"issue":"11","key":"2021121110281285400_CIT0124","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"2021121110281285400_CIT0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation."},{"issue":"1","key":"2021121110281285400_CIT0126","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"issue":"12","key":"2021121110281285400_CIT0127","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"2021121110281285400_CIT0128","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"van Baar","year":"2018","journal-title":"Diabetes Care."},{"issue":"12","key":"2021121110281285400_CIT0129","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"2021121110281285400_CIT0130","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jcjd.2017.11.004","article-title":"Chronic kidney disease in diabetes","volume":"42","author":"McFarlane","year":"2018","journal-title":"Can J Diabetes."},{"issue":"2","key":"2021121110281285400_CIT0131","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1213\/ANE.0000000000002377","article-title":"Perioperative considerations for the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"126","author":"Peacock","year":"2018","journal-title":"Anesth Analg."},{"issue":"24","key":"2021121110281285400_CIT0132","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.116.024764","article-title":"Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility","volume":"134","author":"Cherney","year":"2016","journal-title":"Circulation."},{"issue":"3","key":"2021121110281285400_CIT0133","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.ajkd.2016.03.410","article-title":"No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis?","volume":"68","author":"Perkins","year":"2016","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"2021121110281285400_CIT0134","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MNH.0000000000000343","article-title":"Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?","volume":"26","author":"Rajasekeran","year":"2017","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"7","key":"2021121110281285400_CIT0135","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care."},{"key":"2021121110281285400_CIT0136","article-title":"Perioperative considerations for the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes","author":"Peacock","year":"2017","journal-title":"Anesth Anal"},{"issue":"5","key":"2021121110281285400_CIT0137","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1172\/JCI115179","article-title":"Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C","volume":"87","author":"Tesfamariam","year":"1991","journal-title":"J Clin Invest."},{"issue":"106","key":"2021121110281285400_CIT0138","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/sj.ki.5002386","article-title":"The role of protein kinase C activation in diabetic nephropathy","author":"Noh","year":"2007","journal-title":"Kidney Int Suppl."},{"issue":"3","key":"2021121110281285400_CIT0139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1472-8206.2008.00583.x","article-title":"Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications","volume":"22","author":"Budhiraja","year":"2008","journal-title":"Fundam Clin Pharmacol."},{"issue":"4","key":"2021121110281285400_CIT0140","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2337\/db12-1666","article-title":"Tandem inhibition of PKC in Di\u03b1\u03b2etic nephropathy: it takes two to tango?","volume":"62","author":"Thallas-Bonke","year":"2013","journal-title":"Diabetes."},{"issue":"7","key":"2021121110281285400_CIT0141","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/aps.2016.172","article-title":"LY333531, a PKC\u03b2 inhibitor, attenuates glomerular endothelial cell apoptosis in the early stage of mouse diabetic nephropathy via down-regulating swiprosin-1","volume":"38","author":"Wang","year":"2017","journal-title":"Acta Pharmacol Sin."},{"issue":"1","key":"2021121110281285400_CIT0142","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2337\/dc08-1609","article-title":"Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study","volume":"32","author":"Cherney","year":"2009","journal-title":"Diabetes Care."},{"issue":"4","key":"2021121110281285400_CIT0143","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/dc06-2079","article-title":"Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes","volume":"30","author":"Gilbert","year":"2007","journal-title":"Diabetes Care."},{"issue":"11","key":"2021121110281285400_CIT0144","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care."},{"issue":"1","key":"2021121110281285400_CIT0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/hh0102.102359","article-title":"Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans","volume":"90","author":"Beckman","year":"2002","journal-title":"Circ Res."},{"issue":"1","key":"2021121110281285400_CIT0146","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10557-008-6144-5","article-title":"Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus","volume":"23","author":"Mehta","year":"2009","journal-title":"Cardiovasc Drugs Ther."},{"issue":"4","key":"2021121110281285400_CIT0147","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.00840207","article-title":"Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease","volume":"2","author":"Tuttle","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"2021121110281285400_CIT0148","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/j.ajkd.2014.11.024","article-title":"Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: results from a randomized trial","volume":"65","author":"Tuttle","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"2021121110281285400_CIT0149","doi-asserted-by":"crossref","first-page":"F1276","DOI":"10.1152\/ajprenal.00396.2014","article-title":"Targeting NADPH oxidase with a novel dual Nox1\/Nox4 inhibitor attenuates renal pathology in type 1 diabetes","volume":"308","author":"Gorin","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"issue":"5","key":"2021121110281285400_CIT0150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00125-017-4215-5","article-title":"Combined NOX1\/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease","volume":"60","author":"Gray","year":"2017","journal-title":"Diabetologia."},{"issue":"1","key":"2021121110281285400_CIT0151","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1038\/s41598-018-36344-w","article-title":"AKF-PD alleviates diabetic nephropathy via blocking the RAGE\/AGEs\/NOX and PKC\/NOX pathways","volume":"9","author":"Qin","year":"2019","journal-title":"Sci Rep."},{"key":"2021121110281285400_CIT0152","article-title":"Safety and efficacy of oral GKT1377831 in patient with type 2 diabetes and albuminuria","author":"Genkyotex","year":"2015","journal-title":"NCT02010242"},{"issue":"5","key":"2021121110281285400_CIT0153","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1113\/EP086204","article-title":"NOX5: molecular biology and pathophysiology","volume":"104","author":"Touyz","year":"2019","journal-title":"Exp Physiol."},{"issue":"10","key":"2021121110281285400_CIT0154","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.2337\/db16-1585","article-title":"NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy","volume":"66","author":"Jha","year":"2017","journal-title":"Diabetes."},{"issue":"6","key":"2021121110281285400_CIT0155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000475890","article-title":"Targeting the KEAP1-NRF2 system to prevent kidney disease progression","volume":"45","author":"Nezu","year":"2017","journal-title":"Am J Nephrol."},{"issue":"4","key":"2021121110281285400_CIT0156","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med."},{"issue":"26","key":"2021121110281285400_CIT0157","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med."},{"key":"2021121110281285400_CIT0158","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2018.06.001","article-title":"AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions","volume":"833","author":"Sanajou","year":"2018","journal-title":"Eur J Pharmacol."},{"key":"2021121110281285400_CIT0159","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.pathol.4.110807.092150","article-title":"A glimpse of various pathogenetic mechanisms of diabetic nephropathy","volume":"6","author":"Kanwar","year":"2011","journal-title":"Annu Rev Pathol."},{"issue":"6","key":"2021121110281285400_CIT0160","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.metabol.2010.08.009","article-title":"Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autophagic clearance of advanced glycation end products: Dispo85E, an HGF inducer, as a potential botanical drug","volume":"60","author":"Peng","year":"2011","journal-title":"Metabolism."},{"issue":"3","key":"2021121110281285400_CIT0161","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ki.2010.134","article-title":"Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy","volume":"78","author":"Penfold","year":"2010","journal-title":"Kidney Int."},{"issue":"6","key":"2021121110281285400_CIT0162","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/db16-1281","article-title":"RAGE-Aptamer blocks the development and progression of experimental diabetic nephropathy","volume":"66","author":"Matsui","year":"2017","journal-title":"Diabetes."},{"issue":"1","key":"2021121110281285400_CIT0163","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.kisu.2017.10.005","article-title":"Novel therapies for diabetic kidney disease","volume":"8","author":"Cherney","year":"2018","journal-title":"Kidney Int Suppl (2011)."},{"issue":"10","key":"2021121110281285400_CIT0164","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120365","article-title":"Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"2021121110281285400_CIT0165","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1681\/ASN.2016020177","article-title":"Of inflammasomes and alarmins: IL-1\u03b2 and IL-1\u03b1 in kidney disease","volume":"27","author":"Anders","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"23","key":"2021121110281285400_CIT0166","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation."},{"issue":"12","key":"2021121110281285400_CIT0167","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"issue":"21","key":"2021121110281285400_CIT0168","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of Interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"2021121110281285400_CIT0169","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/JLB.MR1217-489R","article-title":"The role of IL-20 in chronic kidney disease and diabetic nephropathy: pathogenic and therapeutic implications","volume":"104","author":"Chang","year":"2018","journal-title":"J Leukoc Biol."},{"issue":"6","key":"2021121110281285400_CIT0170","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/art.39083","article-title":"Efficacy and safety of anti-interleukin-20 monoclonal antibody in patients with rheumatoid arthritis: a randomized phase IIa trial","volume":"67","author":"\u0160enolt","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"2021121110281285400_CIT0171","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.ki.5002531","article-title":"Apoptosis in the kidneys of patients with type II diabetic nephropathy","volume":"72","author":"Verzola","year":"2007","journal-title":"Kidney Int."},{"issue":"10","key":"2021121110281285400_CIT0172","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1172\/JCI99768","article-title":"ASK1 contributes to fibrosis and dysfunction in models of kidney disease","volume":"128","author":"Liles","year":"2018","journal-title":"J Clin Invest."},{"issue":"1","key":"2021121110281285400_CIT0173","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12033-007-0053-x","article-title":"ASK family proteins in stress response and disease","volume":"37","author":"Fujisawa","year":"2007","journal-title":"Mol Biotechnol."},{"issue":"1","key":"2021121110281285400_CIT0174","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000369152","article-title":"Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease","volume":"129","author":"Lin","year":"2015","journal-title":"Nephron."},{"issue":"10","key":"2021121110281285400_CIT0175","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"2021121110281285400_CIT0176","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/13543784.2016.1196184","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","volume":"25","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin Investig Drugs."},{"issue":"2","key":"2021121110281285400_CIT0177","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2005080859","article-title":"Leukocyte recruitment and vascular injury in diabetic nephropathy","volume":"17","author":"Galkina","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"2021121110281285400_CIT0178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.2057","article-title":"Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy","volume":"16","author":"Tashiro","year":"2002","journal-title":"J Clin Lab Anal."},{"issue":"1","key":"2021121110281285400_CIT0179","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajpath.2011.03.004","article-title":"Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease","volume":"179","author":"Darisipudi","year":"2011","journal-title":"Am J Pathol."},{"issue":"11","key":"2021121110281285400_CIT0180","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00125-009-1493-6","article-title":"Podocytes produce homeostatic chemokine stromal cell-derived factor-1\/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes","volume":"52","author":"Sayyed","year":"2009","journal-title":"Diabetologia."},{"issue":"9","key":"2021121110281285400_CIT0181","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021121110281285400_CIT0182","first-page":"307","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol Dial Transplant."},{"issue":"21","key":"2021121110281285400_CIT0183","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/eurheartj\/ehr170","article-title":"Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes","volume":"32","author":"Albaghdadi","year":"2011","journal-title":"Eur Heart J."},{"issue":"12","key":"2021121110281285400_CIT0184","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1291\/hypres.26.999","article-title":"Activation of protein kinase C and nicotinamide adenine dinucleotide phosphate oxidase in leukocytes of spontaneously hypertensive rats","volume":"26","author":"Maeda","year":"2003","journal-title":"Hypertens Res."},{"issue":"2","key":"2021121110281285400_CIT0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfs429","article-title":"Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases","volume":"28","author":"Morales","year":"2013","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"2021121110281285400_CIT0186","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"issue":"Suppl 4","key":"2021121110281285400_CIT0187","first-page":"iv82","article-title":"Effects of weight loss on renal function in obese CKD patients: a systematic review","volume":"28","author":"Bolignano","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2021121110281285400_CIT0188","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J."},{"issue":"4","key":"2021121110281285400_CIT0189","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications."},{"issue":"31","key":"2021121110281285400_CIT0190","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J."},{"issue":"9","key":"2021121110281285400_CIT0191","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"Jama."},{"issue":"2","key":"2021121110281285400_CIT0192","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.113.205286","article-title":"Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention","volume":"346","author":"Stuart","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"key":"2021121110281285400_CIT0193","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2369-13-166","article-title":"Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion","volume":"13","author":"Stuart","year":"2012","journal-title":"BMC Nephrol."},{"issue":"3","key":"2021121110281285400_CIT0194","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"2021121110281285400_CIT0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"2021121110281285400_CIT0196","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"1","key":"2021121110281285400_CIT0197","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.109.132670","article-title":"Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease","volume":"54","author":"Dhaun","year":"2009","journal-title":"Hypertension."},{"issue":"11","key":"2021121110281285400_CIT0198","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/ndt\/gfm364","article-title":"Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease","volume":"22","author":"Dhaun","year":"2007","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"2021121110281285400_CIT0199","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2337\/db15-1413","article-title":"Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy","volume":"65","author":"Boels","year":"2016","journal-title":"Diabetes."},{"issue":"1","key":"2021121110281285400_CIT0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ckj\/sfs001","article-title":"Endothelin and the podocyte","volume":"5","author":"Barton","year":"2012","journal-title":"Clin Kidney J."},{"issue":"9","key":"2021121110281285400_CIT0201","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nrneph.2009.111","article-title":"Pharmacology: defining the optimal dose of a new drug: a crucial decision","volume":"5","author":"Heerspink","year":"2009","journal-title":"Nat Rev Nephrol."},{"issue":"5","key":"2021121110281285400_CIT0202","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"2021121110281285400_CIT0203","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.13245","article-title":"Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"2021121110281285400_CIT0204","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2021121110281285400_CIT0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2008.07.021","article-title":"Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and\/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial","volume":"53","author":"Waanders","year":"2009","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"2021121110281285400_CIT0206","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2021121110281285400_CIT0207","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ejhf.267","article-title":"Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?","volume":"17","author":"Ruggenenti","year":"2015","journal-title":"Eur J Heart Fail."},{"issue":"17","key":"2021121110281285400_CIT0208","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med."},{"issue":"10","key":"2021121110281285400_CIT0209","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2165\/00003495-200161100-00002","article-title":"Renal effects of adenosine A1-receptor antagonists in congestive heart failure","volume":"61","author":"Gottlieb","year":"2001","journal-title":"Drugs."},{"issue":"15","key":"2021121110281285400_CIT0210","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation."},{"key":"2021121110281285400_CIT0211","doi-asserted-by":"crossref","DOI":"10.2337\/dc18-2173","article-title":"Uric acid is an independent risk factor for decline in kidney function, cardiovascular event and mortality in patients with type 1 diabetes","author":"Pilemann-Lyberg","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"2021121110281285400_CIT0212","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/dom.13665","article-title":"Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes","volume":"21","author":"Lytvyn","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2021121110281285400_CIT0213","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00592-014-0611-1","article-title":"Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study","volume":"51","author":"Bjornstad","year":"2014","journal-title":"Acta Diabetol."},{"issue":"8","key":"2021121110281285400_CIT0214","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"2021121110281285400_CIT0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"2021121110281285400_CIT0216","first-page":"128","article-title":"Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients","volume":"4","author":"Momeni","year":"2010","journal-title":"Iran J Kidney Dis."},{"issue":"1","key":"2021121110281285400_CIT0217","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","article-title":"Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial","volume":"58","author":"Miao","year":"2011","journal-title":"Hypertension."},{"issue":"1","key":"2021121110281285400_CIT0218","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s11671-017-2060-6","article-title":"Direct magnetic relief recording using As40S60: Mn-Se nanocomposite multilayer structures","volume":"12","author":"Stronski","year":"2017","journal-title":"Nanoscale Res Lett."},{"issue":"4","key":"2021121110281285400_CIT0219","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diab Rep."},{"issue":"8","key":"2021121110281285400_CIT0220","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2337\/dc19-0342","article-title":"Preventing early renal loss in diabetes (PERL) study: a randomized double-blinded trial of allopurinol-rationale, design, and baseline data","volume":"42","author":"Afkarian","year":"2019","journal-title":"Diabetes Care."},{"issue":"18","key":"2021121110281285400_CIT0221","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.96.18.10397","article-title":"Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats","volume":"96","author":"Bardoux","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"2021121110281285400_CIT0222","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jdiacomp.2016.04.012","article-title":"Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes","volume":"30","author":"Bjornstad","year":"2016","journal-title":"J Diabetes Complications."},{"issue":"1","key":"2021121110281285400_CIT0223","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-018-0753-5","article-title":"Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes","volume":"17","author":"Velho","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"2021121110281285400_CIT0224","article-title":"Copeptin and estimated insulin sensitivity in adults with and without type 1 diabetes: The CACTI Study","author":"Jensen","year":"2018","journal-title":"Can J Diabetes"},{"issue":"2","key":"2021121110281285400_CIT0225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jdiacomp.2016.11.015","article-title":"Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: a brief report from the T1D exchange Biobank","volume":"31","author":"Bjornstad","year":"2017","journal-title":"J Diabetes Complications."},{"issue":"1","key":"2021121110281285400_CIT0226","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ndt\/gfp409","article-title":"Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus","volume":"25","author":"Boone","year":"2010","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"2021121110281285400_CIT0227","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/cc12530","article-title":"Renal oxygenation in clinical acute kidney injury","volume":"17","author":"Ricksten","year":"2013","journal-title":"Crit Care."},{"issue":"8","key":"2021121110281285400_CIT0228","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1399-6576.2009.02037.x","article-title":"Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients","volume":"53","author":"Bragadottir","year":"2009","journal-title":"Acta Anaesthesiol Scand."},{"issue":"2","key":"2021121110281285400_CIT0229","doi-asserted-by":"crossref","first-page":"F265","DOI":"10.1152\/ajprenal.00354.2000","article-title":"Endogenous vasopressin regulates Na-K-ATPase and Na(+)-K(+)-Cl(-) cotransporter rbsc-1 in rat outer medulla","volume":"282","author":"Bertuccio","year":"2002","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"2021121110281285400_CIT0230","first-page":"247","article-title":"Coordinate control of Na,K-atpase mRNA expression by aldosterone, vasopressin and cell sodium delivery in the cortical collecting duct","volume":"47","author":"Blot-Chabaud","year":"2001","journal-title":"Cell Mol Biol (Noisy-Le-Grand)."},{"issue":"3","key":"2021121110281285400_CIT0231","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1996.101","article-title":"Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles","volume":"49","author":"Tamaki","year":"1996","journal-title":"Kidney Int."},{"issue":"6","key":"2021121110281285400_CIT0232","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jdiacomp.2017.04.005","article-title":"Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes","volume":"31","author":"El Boustany","year":"2017","journal-title":"J Diabetes Complications."},{"key":"2021121110281285400_CIT0233","first-page":"FR-PO101","article-title":"Selective vasopressin V1a receptor antagonism improves renal oxygenation and perfusion in acute kidney injury","author":"Cernecka","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"2021121110281285400_CIT0234","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.2009.267","article-title":"V1\/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction","volume":"76","author":"Perico","year":"2009","journal-title":"Kidney Int."},{"issue":"5","key":"2021121110281285400_CIT0235","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"2021121110281285400_CIT0236","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","article-title":"Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 trial","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant."},{"issue":"20","key":"2021121110281285400_CIT0237","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2021121110281285400_CIT0238","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","article-title":"Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity","volume":"61","author":"Wong","year":"2012","journal-title":"Gut."},{"issue":"1","key":"2021121110281285400_CIT0239","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.22293","article-title":"Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial","volume":"48","author":"Gin\u00e8s","year":"2008","journal-title":"Hepatology."},{"issue":"6","key":"2021121110281285400_CIT0240","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurjhf\/hfs051","article-title":"The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study","volume":"14","author":"Ghali","year":"2012","journal-title":"Eur J Heart Fail."},{"key":"2021121110281285400_CIT0241","article-title":"Lixivaptan, a novel vasopressin V2 receptor antagonist in development for the treatment of autosomal dominant polycystic kidney disease","author":"Pellegrini","year":"2019","journal-title":"Kidney Week 2017: ABSTRACT: FR-PO326"},{"issue":"4","key":"2021121110281285400_CIT0242","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol."},{"issue":"4","key":"2021121110281285400_CIT0243","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00018-017-2639-1","article-title":"Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential","volume":"75","author":"Yang","year":"2018","journal-title":"Cell Mol Life Sci."},{"issue":"7","key":"2021121110281285400_CIT0244","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1080\/15548627.2015.1049799","article-title":"Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis","volume":"11","author":"Lenoir","year":"2015","journal-title":"Autophagy."},{"issue":"6","key":"2021121110281285400_CIT0245","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","article-title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","volume":"58","author":"Cefalu","year":"2015","journal-title":"Diabetologia."},{"key":"2021121110281285400_CIT0246","doi-asserted-by":"crossref","first-page":"3560238","DOI":"10.1155\/2017\/3560238","article-title":"Podocyte autophagy: a potential therapeutic target to prevent the progression of diabetic nephropathy","volume":"2017","author":"Liu","year":"2017","journal-title":"J Diabetes Res."},{"issue":"6","key":"2021121110281285400_CIT0247","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.yexcr.2013.01.018","article-title":"High glucose induces autophagy in podocytes","volume":"319","author":"Ma","year":"2013","journal-title":"Exp Cell Res."},{"issue":"6","key":"2021121110281285400_CIT0248","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J Clin Invest."},{"issue":"6","key":"2021121110281285400_CIT0249","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"G\u00f6del","year":"2011","journal-title":"J Clin Invest."},{"issue":"1","key":"2021121110281285400_CIT0250","doi-asserted-by":"crossref","DOI":"10.3390\/cells8010061","article-title":"Autophagy in chronic kidney diseases","volume":"8","author":"Lin","year":"2019","journal-title":"Cells"},{"issue":"1","key":"2021121110281285400_CIT0251","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kint.2015.10.007","article-title":"Therapy for kidney fibrosis: is the Src kinase a potential target?","volume":"89","author":"Zhou","year":"2016","journal-title":"Kidney Int."},{"issue":"1","key":"2021121110281285400_CIT0252","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ki.2015.293","article-title":"Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis","volume":"89","author":"Yan","year":"2016","journal-title":"Kidney Int."},{"issue":"11","key":"2021121110281285400_CIT0253","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.2337\/db12-1010","article-title":"Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice","volume":"62","author":"Taniguchi","year":"2013","journal-title":"Diabetes."},{"issue":"3","key":"2021121110281285400_CIT0254","doi-asserted-by":"crossref","first-page":"F721","DOI":"10.1152\/ajprenal.00141.2017","article-title":"Src family kinases in chronic kidney disease","volume":"313","author":"Wang","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"issue":"11","key":"2021121110281285400_CIT0255","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00125-017-4394-0","article-title":"Prolonged exposure of mouse and human podocytes to insulin induces insulin resistance through lysosomal and proteasomal degradation of the insulin receptor","volume":"60","author":"Lay","year":"2017","journal-title":"Diabetologia."},{"issue":"1","key":"2021121110281285400_CIT0256","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1681\/ASN.2005070757","article-title":"Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure","volume":"17","author":"Nangaku","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"2021121110281285400_CIT0257","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.ki.5000221","article-title":"The VHL\/HIF oxygen-sensing pathway and its relevance to kidney disease","volume":"69","author":"Haase","year":"2006","journal-title":"Kidney Int."},{"issue":"4","key":"2021121110281285400_CIT0258","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ncpneph0757","article-title":"Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy","volume":"4","author":"Singh","year":"2008","journal-title":"Nat Clin Pract Nephrol."},{"issue":"7","key":"2021121110281285400_CIT0259","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care."},{"issue":"16","key":"2021121110281285400_CIT0260","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95107","article-title":"Renal tubule insulin receptor modestly promotes elevated blood pressure and markedly stimulates glucose reabsorption","volume":"3","author":"Nizar","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"2021121110281285400_CIT0261","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc09-2340","article-title":"Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes","volume":"33","author":"Cherney","year":"2010","journal-title":"Diabetes Care."},{"issue":"4","key":"2021121110281285400_CIT0262","doi-asserted-by":"crossref","first-page":"F667","DOI":"10.1152\/ajprenal.00400.2017","article-title":"Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with Type 1 diabetes mellitus","volume":"314","author":"Lovshin","year":"2018","journal-title":"Am J Physiol Renal Physiol."},{"issue":"10","key":"2021121110281285400_CIT0263","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/ndt\/gfv121","article-title":"Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with type 1 diabetes","volume":"30","author":"Bjornstad","year":"2015","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"2021121110281285400_CIT0264","first-page":"F423","article-title":"Is the function of the renal papilla coupled exclusively to an anaerobic pattern of metabolism?","volume":"236","author":"Cohen","year":"1979","journal-title":"Am J Physiol."},{"key":"2021121110281285400_CIT0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev.ph.48.030186.000301","article-title":"ATP and the regulation of renal cell function","volume":"48","author":"Soltoff","year":"1986","journal-title":"Annu Rev Physiol."},{"issue":"5","key":"2021121110281285400_CIT0266","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"K\u00f6rner","year":"1994","journal-title":"Diabetes."},{"issue":"6","key":"2021121110281285400_CIT0267","doi-asserted-by":"crossref","first-page":"F1217","DOI":"10.1152\/ajprenal.00294.2016","article-title":"Solute transport and oxygen consumption along the nephrons: effects of Na+ transport inhibitors","volume":"311","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"issue":"6","key":"2021121110281285400_CIT0268","doi-asserted-by":"crossref","first-page":"F1378","DOI":"10.1152\/ajprenal.00293.2016","article-title":"A computational model for simulating solute transport and oxygen consumption along the nephrons","volume":"311","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"issue":"11","key":"2021121110281285400_CIT0269","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"2021121110281285400_CIT0270","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-003-1155-z","article-title":"Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension","volume":"46","author":"Palm","year":"2003","journal-title":"Diabetologia."},{"issue":"2","key":"2021121110281285400_CIT0271","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1440-1681.12034","article-title":"Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension","volume":"40","author":"Hansell","year":"2013","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"8","key":"2021121110281285400_CIT0272","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1681\/ASN.2010111143","article-title":"Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging","volume":"22","author":"Inoue","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"2021121110281285400_CIT0273","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0002-9629(15)33943-4","article-title":"Disturbances in renal autoregulation and the susceptibility to hypertension-induced chronic kidney disease","volume":"328","author":"Palmer","year":"2004","journal-title":"Am J Med Sci."},{"issue":"8","key":"2021121110281285400_CIT0274","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/bph.12468","article-title":"Targeting mitochondrial cardiolipin and the cytochrome c\/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis","volume":"171","author":"Birk","year":"2014","journal-title":"Br J Pharmacol."},{"issue":"8","key":"2021121110281285400_CIT0275","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharmacol."},{"issue":"8","key":"2021121110281285400_CIT0276","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1681\/ASN.2012121216","article-title":"The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin","volume":"24","author":"Birk","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"2021121110281285400_CIT0277","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1681\/ASN.2010080808","article-title":"Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury","volume":"22","author":"Szeto","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"2021121110281285400_CIT0278","doi-asserted-by":"crossref","first-page":"15862","DOI":"10.1038\/s41598-018-34251-8","article-title":"The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes","volume":"8","author":"Escribano-Lopez","year":"2018","journal-title":"Sci Rep."},{"issue":"5","key":"2021121110281285400_CIT0279","first-page":"F357","article-title":"Stoichiometry and coupling of active transport to oxidative metabolism in epithelial tissues","volume":"240","author":"Mandel","year":"1981","journal-title":"Am J Physiol."},{"issue":"1","key":"2021121110281285400_CIT0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/157339908783502361","article-title":"Role of inflammation in diabetic nephropathy","volume":"4","author":"Fornoni","year":"2008","journal-title":"Curr Diabetes Rev."}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnz010\/30250452\/bnz010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/41\/2\/202\/41723932\/edrv_41_2_202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/41\/2\/202\/41723932\/edrv_41_2_202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T22:14:16Z","timestamp":1695334456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/41\/2\/202\/5601424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":280,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,21]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnz010","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,10,21]]}}}